A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Subjects With Osteomyelitis Known or Suspected to be Due to Gram- Positive Organisms

Trial Profile

A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Subjects With Osteomyelitis Known or Suspected to be Due to Gram- Positive Organisms

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Osteomyelitis
  • Focus Therapeutic Use
  • Sponsors Durata Therapeutics
  • Most Recent Events

    • 06 Aug 2017 Planned End Date changed from 1 Nov 2017 to 23 Dec 2017.
    • 06 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 23 Dec 2017.
    • 06 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top